$12.13
−6.11%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.61
From 52W high−32.61%
Volume488214.00
Market cap$140.60M
P/E (TTM)—
P/S (TTM)43.1x
Div yield—
Key dataSep 18, 2026
Open
$12.61
From 52W high
−32.61%
Volume
488214.00
Market cap
$140.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
64.3
MomentumView details →
1D Return
−6.11%
YTD Return
+71.47%
SummaryUpdated Jun 1, 2026
Predictive Oncology Inc. (NASDAQ:POAI) is a knowledge-driven biotechnology company founded in 2002 and headquartered in Eagan, Minnesota. Originally incorporated as Precision Therapeutics Inc., the company rebranded to its current name in June 2019 to better reflect its focus on artificial intelligence-driven cancer research. The company has evolved from a traditional medical device manufacturer into a science-driven organization that leverages artificial intelligence and machine learning to advance personalized cancer therapies and drug discovery processes.
Similar companies
Latest newsMore news →
DataMeds AI, Inc. issued 636,328 shares of common stock and a $1,363,672 convertible promissory note to Axe Compute Inc. in a private placement valued at $1.5 million.4d agoAxe Compute and Duos Technologies announced agreements to add up to 55 MW of AI data center capacity across multiple U.S. locations.34d agoAxe Compute Inc. reported financial results for the second quarter ended June 30, 2026, with revenue growing more than 90x sequentially from Q1 2026 and more than $2.8 billion in new contracts signed during the quarter, bringing 2026 signed contracted value to over $3 billion.37d ago